Beta Pharma

Beta Pharma is a private, late-stage oncology biotech with a diversified pipeline of small molecule inhibitors targeting key oncogenic drivers like EGFR, CDK4/6, c-Met, KRAS, and FGFR. The company originated from a contract research organization (CRO) and leverages its synthetic chemistry expertise to develop novel therapeutics, with its lead asset, icotinib, already commercialized in China. Its business model is primarily therapeutic, focusing on both internal development and external partnerships to bring best-in-class oncology drugs to market. While likely pre-revenue in the US, it has a strategic history of partnering for development and commercialization in specific regions.

Medicinal chemistry and small molecule drug discovery platform rooted in synthetic chemistry expertise, focused on inhibitors of validated oncogenic targets like EGFR, CDK4/6, c-Met, KRAS, and FGFR.

Beta Pharma operates in highly competitive fields. Its EGFR inhibitors compete against AstraZeneca's osimertinib (the dominant 3rd gen TKI) and others. Its CDK4/6 inhibitor faces entrenched market leaders from Pfizer, Novartis, and Lilly. The KRAS and FGFR spaces are also crowded with numerous clinical-stage competitors from both large and small companies.